Fasano, S;
Gordon, P;
Hajji, R;
Loyo, E;
Isenberg, DA;
(2017)
Rituximab in the treatment of inflammatory myopathies: a review.
Rheumatology
, 56
(1)
pp. 26-36.
10.1093/rheumatology/kew146.
Preview |
Text
Isenberg_Rituximab in the treatment of inflammatory myopathies_ combined.pdf - Accepted Version Download (549kB) | Preview |
Abstract
Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.
Type: | Article |
---|---|
Title: | Rituximab in the treatment of inflammatory myopathies: a review |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1093/rheumatology/kew146 |
Publisher version: | http://dx.doi.org/10.1093/rheumatology/kew146 |
Language: | English |
Additional information: | This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record, Fasano, S; Gordon, P; Hajji, R; Loyo, E; Isenberg, DA; (2017) Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology, 56 (1) pp. 26-36, is available online at: http://dx.doi.org/10.1093/rheumatology/kew146. |
Keywords: | anti-synthetase syndrome, dermatomyositis, inflammatory myopathies, polymyositis, rituximab |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
URI: | https://discovery.ucl.ac.uk/id/eprint/1536421 |
Archive Staff Only
View Item |